High antioxidant capacity may alter the severity and treatment of hypoxic-ischemic encephalopathy in newborns
Main Article Content
Abstract
Background: We compared prooxidant and antioxidant capacity in newborns with mild, moderate, and severe hypoxic-ischemic encephalopathy with a control group.
Methods: Twenty-eight newborns were included in the perinatal asphyxia group and 32 healthy newborns were included in the control group. Newborns in the perinatal asphyxia group were divided into two groups as mild hypoxic-ischemic encephalopathy (n=12) and moderate+severe hypoxic-ischemic encephalopathy (n=16) groups according to the Sarnat Classification. Basal venous blood samples were taken from the newborns in the mild hypoxic-ischemic encephalopathy (n=12), moderate+severe hypoxic-ischemic encephalopathy (n=16) and the control group (n=32) at the postnatal 1st hour, and the level of total oxidative stress and total antioxidant capacity were studied. Oxidative stress index was calculated as the percent ratio of total oxidative stress to antioxidant capacity in all newborns.
Results: Total antioxidant capacity level was significantly higher in the mild hypoxic-ischemic encephalopathy group (n=12) compared to the control group (n=32) (p=0.04). No statistically significant difference was found between the mild hypoxic-ischemic encephalopathy, moderate+severe hypoxic-ischemic encephalopathy and control groups in terms of total oxidative stress and oxidative stress index
Conclusion: High antioxidant capacity predicted the diagnosis of mild hypoxic-ischemic encephalopathy. There is a need for studies showing a cut-off value for antioxidant capacity as a biomarker in the diagnosis of HIE. Maternally given antioxidant therapy can be neuroprotective in newborns with hypoxic-ischemic encephalopathy where there is a clinical picture of mild hypoxic-ischemic encephalopathy in newborns with a high antioxidant capacity. Further studies are needed to evaluate whether maternal antioxidants are neuroprotective in newborns.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Kurinczuk JJ, White-KoningM, Badawi N. Epidemiology of neonatal encephalopathy and hypoxic-ischaemic encephalopathy. Early Hum Dev. 2010; 86: 329–338.
3. Valko M, Leibfritz D, Moncol J, Cronin MTD, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol. 2007; 39: 44–84.
4. Lushchak VI. Free radicals, reactive oxygen species, oxidative stress and its classification. Chem. Biol. Interact. 2014; 224: 164–175.
5. Buonocore G, Perrone S, Tataranno ML. Oxidative stress in the newborn. Oxid. Med. Cell. Longev. 2017; 2017:1094247.
6. Chrysanthy İ,Kaindl AM. Neuronal death and oxidative stress in the developing brain. Antioxid Redox Signal. 2011;14:1535-1550.
7. Neonatal encephalopathy and neurologic outcome, second edition. Report of the American College of Obstetricians and Gynecologists' Task Force on Neonatal Encephalopathy. Obstet Gynecol. 2014; 123:896.
8. Sarnat HB, Sarnat MS. Neonatal encephalopathy following fetal distress. A clinical and electroencephalographic study. Arch Neurol. 1976;33:696-705.
9. Karaarslan S, Alp H, Baysal T, Cimen D, Ors R, Oran B. Is myocardial performance index useful in differential diagnosis of moderate and severe hypoxic ischaemic encephalopathy? A serial Doppler echocardiographic evaluation. Cardiol Young. 2012;22(3):335-340.
10. O. Erel A new automated colorimetric method for measuring total oxidant status. Clin Biochem. 2005; 38: 1103-1111.
11. O. Erel. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem. 2004; 37: 277-285.
12. El Bana SM, Esam Maher S, Fawzy Gaber A, Shaker Aly S. Serum and urinary malondialdehyde (MDA), uric acid, and protein as markers of perinatal asphyxia. Electron Physician. 2016; 8: 2614–2619.
13. Mondal N, Bhat B V, Banupriya C, Koner B. C. Oxidative stress in perinatal asphyxia in relation to outcome. Indian J. Pediatr. 2010; 77: 515–517.
14. Negro S, Manon JN, Blenders NL, Tataranno ML, Coviello C, Linda S. et al. Early prediction of hypoxic-ischemic brain injury by a new panel of biomarkers in a population of term newborns. Oxid. Med. Cell. Longev. 2018: 7608108.
15. Chafer-Pericas C, Cernada M, Rahkonen L, Stefanovic V, Andersson S, Vento M. Preliminary case control study to establish the correlation between novel peroxidation biomarkers in cord serum and the severity of hypoxic ischemic encephalopathy. Free Radic. Biol. Med. 2016: 97; 244–249.
16. Kumar A, Ramakrishna S. V. K, Basu S, Rao GRK. Oxidative stress in perinatal asphyxia. Pediatr Neurol. 2008; 38: 181–185.
17. Miller SL, Yan EB, Castillo-Meléndez M, Jenkin G, Walker DW. Melatonin provides neuroprotection in the late-gestation fetal sheep brain in response to umbilical cord occlusion. Dev. Neurosci. 2005; 27: 200–210.
18. Torrance HL, Benders MJ, Derks JB, Rademaker CMA, Bos AF, Van Den Berg P et al. Maternal allopurinol during fetal hypoxia lowers cord blood levels of the brain injury marker S-100B. Pediatrics. 2009; 124: 350–357.
19. Kaandorp JJ, Benders MJNL, Schuit E,Rademaker CMA, Oudjik MA, Porath MM. Maternal allopurinol administration during suspected fetal hypoxia: a novel neuroprotective intervention? A multicentre randomised placebo controlled trial. Arch. Dis. Child. Fetal Neonatal Ed. 2015; 100: 216–223.
20. Klumper J, Kaandorp JJ, Schuit E, Groenendaal F, Koopman-Esseboom C, Mulder EJ.H.et.al. Behavioral and neurodevelopmental outcome of children after maternal allopurinol administration during suspected fetal hypoxia: 5-year followup of the ALLO-trial. PLoS ONE. 2018: 13; 0201063.
21. Liu J-X, Zheng D, Chen L, Chen S, Min J-W. Nuclear Factor Erythroid 2-Related Factor 2 as a Potential Therapeutic Target in Neonatal Hypoxic-Ischemic Encephalopathy. J. Integr. Neurosci. 2024; 23(5): 103.